Hims & Hers Health, Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating potential shareholder action claims on behalf of shareholders of Hims & Hers Health, Inc. ("Hims & Hers Health" or the "Company") (HIMS) against certain of its directors and officers for alleged breaches of fiduciary duties and other violations of law. Concerned shareholders are advised to contact the firm now.

The investigation concerns whether Hims & Hers Health's board of directors and executive officers allegedly breached their fiduciary duties to the Company and its shareholders by failing to maintain adequate internal controls and oversight systems.

On June 23, 2025, Novo Nordisk publicly terminated its collaboration with Hims & Hers Health, citing concerns regarding the Company's purported illegal mass compounding and deceptive marketing practices related to weight-loss drugs. According to Novo Nordisk, Hims & Hers Health allegedly failed to comply with laws prohibiting mass sales of compounded drugs and engaged in marketing practices that may have put patient safety at risk. These revelations followed the U.S. Food and Drug Administration's February 2025 announcement that compounded semaglutide would no longer be permitted after May 22, 2025, ending a temporary exemption that had allowed such sales during a nationwide shortage.

The June 23, 2025, disclosure resulted in a significant market reaction, with Hims & Hers Health's stock price falling approximately 32% intraday, erasing billions of dollars in market value. This decline was not attributable to broader market factors, but rather appeared to be directly tied to the corrective disclosure regarding the Company’s business practices and regulatory compliance. Additional concerns have emerged regarding the Company’s public statements about its partnership with Novo Nordisk and its optimistic sales forecasts, which seemingly failed to account for regulatory changes and the end of the compounding exemption. Furthermore, reports indicate that certain executives, including the CEO, engaged in substantial stock sales prior to the public disclosure of these issues, raising questions about potential insider activity and governance oversight.

A shareholder derivative action seeks to recover damages on behalf of the Company and may result in corporate governance reforms designed to prevent similar misconduct in the future.

Shareholders who have held Hims & Hers Health stock continuously may be able to pursue claims derivatively on behalf of the Company against responsible directors and officers.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing derivative actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including derivative actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.